Opko Health, Inc. (OPK): Robert A Baron , director of Opko Health, Inc. sold 37,500 shares on May 13, 2016. The Insider selling transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were sold at $9.83 per share for a total value of $368,490.81 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Gamma Investments Trust Frost (CEO) purchased 30,600 shares at $9.54 per share price.On Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price.Also, On Sep 15, 2015, Adam Logal (CFO) purchased 1,000 shares at $9.95 per share price.On Aug 20, 2015, Steven D Rubin (Executive VP-Administration) purchased 2,000 shares at $12.40 per share price.
Opko Health: On Monday, May 16, 2016 heightened volatility was witnessed in Opko Health which led to swings in the share price. The shares opened for trading at $9.83 and hit $10 on the upside , eventually ending the session at $9.97, with a gain of 2.26% or 0.22 points. The heightened volatility saw the trading volume jump to 23,05,166 shares. The 52-week high of the share price is $19.2 and the company has a market cap of $5,458 M . The 52-week low of the share price is at $7.1225.
Company has been under the radar of several Street Analysts.Opko Health is Reiterated by Barrington Research to Outperform while Lowering the Price Target of the company shares to $ 16 from a previous price target of $17 . The Rating was issued on Mar 31, 2016.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.